Glass House Brands (GLAS) Liabilities and Shareholders Equity (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Liabilities and Shareholders Equity of $325.4 million for Q1 2026, up 4.42% year-over-year from $311.6 million in Q1 2025, and up 2.13% quarter-over-quarter from $318.6 million in Q4 2025.
Glass House Brands (GLAS) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $325.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 4.42% year-over-year to $325.4 million; the TTM figure through Mar 2026 stood at $1.3 billion (up 4.64% YoY), while the FY2025 annual figure was $318.6 million, up 2.59% from the prior year.
- Liabilities and Shareholders Equity advanced to $325.4 million in Q1 2026 per GLAS's latest filing, from $318.6 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $350.6 million in Q4 2022 and bottomed at $273.2 million in Q1 2022.
- Historically, Liabilities and Shareholders Equity has averaged $318.2 million across 5 years, with a median of $318.6 million in 2025.
- On a YoY basis, Liabilities and Shareholders Equity climbed as much as 6041.02% in 2022 and fell as far as 61.84% in 2022.
- Glass House Brands' Liabilities and Shareholders Equity stood at $350.6 million in 2022, then fell by 13.36% to $303.8 million in 2023, then grew by 2.21% to $310.5 million in 2024, then advanced by 2.59% to $318.6 million in 2025, then advanced by 2.13% to $325.4 million in 2026.
- Business Quant data shows GLAS's Liabilities and Shareholders Equity at $325.4 million in Q1 2026, $318.6 million in Q4 2025, and $319.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn | 313.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 325.35 Mn |
| Dec 31, 2025 | 318.56 Mn |
| Sep 30, 2025 | 319.82 Mn |
| Jun 30, 2025 | 334.56 Mn |
| Mar 31, 2025 | 311.59 Mn |
| Dec 31, 2024 | 310.50 Mn |
| Sep 30, 2024 | 312.73 Mn |
| Jun 30, 2024 | 305.84 Mn |
| Mar 31, 2024 | 295.25 Mn |
| Dec 31, 2023 | 303.78 Mn |
| Sep 30, 2023 | 341.59 Mn |
| Jun 30, 2023 | 324.60 Mn |
| Mar 31, 2023 | 324.70 Mn |
| Dec 31, 2022 | 350.63 Mn |
| Sep 30, 2022 | 349.56 Mn |
| Jun 30, 2022 | 307.25 Mn |
| Mar 31, 2022 | 273.15 Mn |
| Dec 31, 2021 | 5.71 Mn |
| Sep 30, 2021 | 258.56 Mn |
| Jun 30, 2021 | 203.47 Mn |